Yanlun Gu

1.4k total citations · 1 hit paper
12 papers, 780 citations indexed

About

Yanlun Gu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Yanlun Gu has authored 12 papers receiving a total of 780 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Yanlun Gu's work include Ferroptosis and cancer prognosis (4 papers), Cancer, Lipids, and Metabolism (3 papers) and Prostate Cancer Treatment and Research (3 papers). Yanlun Gu is often cited by papers focused on Ferroptosis and cancer prognosis (4 papers), Cancer, Lipids, and Metabolism (3 papers) and Prostate Cancer Treatment and Research (3 papers). Yanlun Gu collaborates with scholars based in China, United States and United Kingdom. Yanlun Gu's co-authors include Yimin Cui, He Xu, Zhiwei Qiu, Hanxu Zhang, Qian Xiang, Xiaocong Pang, Zhiyan Liu, Ran Xie, Nan Zhao and Xiaocong Pang and has published in prestigious journals such as Frontiers in Immunology, Advanced Science and Signal Transduction and Targeted Therapy.

In The Last Decade

Yanlun Gu

11 papers receiving 769 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting integrin pathways: mechanisms and advances in therapy

2023 610 citations Xiaocong Pang, He Xu et al. Signal Transduction and Targeted Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yanlun Gu China	7	324	131	131	127	110	12	780
He Xu China	7	340 1.0×	131 1.0×	125 1.0×	134 1.1×	106 1.0×	15	773
Zhiyan Liu China	8	332 1.0×	115 0.9×	107 0.8×	136 1.1×	93 0.8×	30	799
Hanxu Zhang China	9	320 1.0×	118 0.9×	124 0.9×	113 0.9×	121 1.1×	31	835
Carla Guenther Finland	9	312 1.0×	137 1.0×	292 2.2×	189 1.5×	109 1.0×	14	841
Marc Llort Asens Finland	7	241 0.7×	131 1.0×	277 2.1×	163 1.3×	91 0.8×	7	707
Amanda Del Rosario United States	14	533 1.6×	80 0.6×	69 0.5×	189 1.5×	115 1.0×	23	1.0k
Alexis Broisat France	18	342 1.1×	128 1.0×	184 1.4×	144 1.1×	73 0.7×	66	1.1k
Brian A. MacDonald United States	9	388 1.2×	162 1.2×	93 0.7×	231 1.8×	172 1.6×	13	923
Mika Pietilä Finland	17	507 1.6×	98 0.7×	95 0.7×	278 2.2×	220 2.0×	24	1.1k

Countries citing papers authored by Yanlun Gu

Since Specialization

Citations

This map shows the geographic impact of Yanlun Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanlun Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanlun Gu more than expected).

Fields of papers citing papers by Yanlun Gu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanlun Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanlun Gu. The network helps show where Yanlun Gu may publish in the future.

Co-authorship network of co-authors of Yanlun Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Yanlun Gu. A scholar is included among the top collaborators of Yanlun Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanlun Gu. Yanlun Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Zhang, Jixin, Junling Zhang, Yanlun Gu, et al.. (2025). Systematic Characterisation and Analysis of Lysyl Oxidase Family Members as Drivers of Tumour Progression and Multiple Drug Resistance. Journal of Cellular and Molecular Medicine. 29(7). e70536–e70536. 1 indexed citations

Zhang, Junling, Qingqing Xiong, Xin Wang, et al.. (2024). Targeting SLITRK4 Restrains Proliferation and Liver Metastasis in Colorectal Cancer via Regulating PI3K/AKT/NFκB Pathway and Tumor‐Associated Macrophage. Advanced Science. 12(1). e2400367–e2400367. 6 indexed citations

Xu, He, Jian Wang, Yanlun Gu, et al.. (2024). IUPHAR ECR review: The cGAS-STING pathway: Novel functions beyond innate immune and emerging therapeutic opportunities. Pharmacological Research. 201. 107063–107063. 16 indexed citations

Gu, Yanlun, Ying Zhou, Jixin Zhang, et al.. (2024). Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer. Advanced Healthcare Materials. 13(28). e2400673–e2400673. 7 indexed citations

Gu, Yanlun, Ying Zhou, Jixin Zhang, et al.. (2024). Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer (Adv. Healthcare Mater. 28/2024). Advanced Healthcare Materials. 13(28).

Li, Wenhui, Mingli Gong, Yanlun Gu, et al.. (2023). Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis. Frontiers in Pharmacology. 14. 1189389–1189389. 23 indexed citations

Pang, Xiaocong, He Xu, Zhiwei Qiu, et al.. (2023). Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. 8(1). 1–1. 610 indexed citations breakdown →

Gu, Yanlun, He Xu, Zhiwei Qiu, et al.. (2023). The challenges and opportunities of αvβ3-based therapeutics in cancer: From bench to clinical trials. Pharmacological Research. 189. 106694–106694. 36 indexed citations

Gong, Mingli, et al.. (2023). Identification of potential ferroptosis-associated biomarkers in rheumatoid arthritis. Frontiers in Immunology. 14. 1197275–1197275. 20 indexed citations

10.

Fang, Jiansong, Mingli Gong, Ran Xie, et al.. (2023). Identification of immune‐associated signatures and potential therapeutic targets for pulmonary arterial hypertension. Journal of Cellular and Molecular Medicine. 27(23). 3864–3877. 6 indexed citations

11.

Wu, Yingchao, Junling Zhang, Yanlun Gu, et al.. (2023). A novel immunogenic cell death–related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer. Frontiers in Immunology. 14. 1162876–1162876. 2 indexed citations

12.

Pang, Xiaocong, Junling Zhang, He Xu, et al.. (2021). SPP1 Promotes Enzalutamide Resistance and Epithelial‐Mesenchymal‐Transition Activation in Castration‐Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways. Oxidative Medicine and Cellular Longevity. 2021(1). 1258–5806602. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact